Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 20 of 20

 
 

Immunovant (NASDAQ:IMVT)

Immunovant logoImmunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. More about Immunovant
 
Trailing Twelve Months EPS: ($2.74)
2025 EPS Estimate: ($2.69)
2026 EPS Estimate: ($3.08)

Current Stock Price
$16.77
Consensus Rating
Moderate Buy
Ratings Breakdown
8 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$38.33 (128.6% Upside)

More Investing Slideshows: